# A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Source: https://onco.cc/trials/nct06385925/  
OnCo record `nct06385925` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TSN1611 in advanced solid tumours, run by Tyligand Pharmaceuticals (Suzhou) Limited, now recruiting.

## Summary

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT06385925 by Tyligand Pharmaceuticals (Suzhou) Limited, with 440 participants planned, started 2024-04-29 and due to reach its primary completion in 2026-10-30. Interventions recorded: TSN1611.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06385925
- Phase: 1/2
- Setting: Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited
- Enrolled: 440

## Sources

- ClinicalTrials.gov NCT06385925: https://clinicaltrials.gov/study/NCT06385925

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06385925.json